224 institutions reported holding KNSA for 2026Q1, together 55% of the company, more than the 219 a quarter earlier. Institutions reporting a position: 224 (as of 2026Q1). Shares held by institutions: 45.4M, long US equity positions only, as reported on Form 13F. Reported value: $2.18B, at 2026-03-31 prices, not today's. Top 5 holders: 23%, of the whole company, between five filers.

KNSAKiniksa Pharmaceuticals International, plc

HealthcareUSD

$78.72

$32.1552 weeks$80.83

Who owns KNSA

224 institutions reported holding KNSA for 2026Q1, together 55% of the company, more than the 219 a quarter earlier.

224

Institutions reporting a position · as of 2026Q1 · up from 219 the quarter before

Shares held by institutions: 45.4M
Shares held by institutions · 55% of the company · long US equity positions only, as reported on Form 13F
Reported value: $2.18B
Reported value · at 2026-03-31 prices, not today's
Top 5 holders: 23%
Top 5 holders · of the whole company, between five filers

Details›

Reporting quarter2026-03-31: 2026Q1
Quarters on record: 32
New positions: 36
Positions exited: 35
Added to: 72
Reduced: 82
Top 10 holdersof the company: 29%

Institutional ownership by quarter, 2018Q2 to 2026Q1
Quarter	Filers	Shares	Reported value
2026Q1	224	45.4M	$2.18B
2025Q4	219	42.9M	$1.77B
2025Q3	201	40.7M	$1.58B
2025Q2	188	39.8M	$1.10B
2025Q1	175	40.0M	$889M
2024Q4	159	39.1M	$773M
2024Q3	175	39.7M	$991M
2024Q2	131	35.3M	$659M
2024Q1	154	38.9M	$768M
2023Q4	142	34.2M	$600M
2023Q3	134	34.9M	$606M
2023Q2	127	31.8M	$448M
2023Q1	132	31.8M	$340M
2022Q4	123	30.1M	$450M
2022Q3	103	29.9M	$383M
2022Q2	91	29.9M	$290M

Largest reported holders, 2026Q1
Holder	Shares	% of company	Value
FMR LLC	6.8M	8.3%	$329M
Rubric Capital Management LP	3.8M	4.5%	$181M
VANGUARD GROUP INC	3.2M	3.8%	$152M
BAKER BROS. ADVISORS LP	2.8M	3.4%	$136M
TANG CAPITAL MANAGEMENT LLC	2.3M	2.7%	$109M
ACADIAN ASSET MANAGEMENT LLC	1.3M	1.6%	$64M
MORGAN STANLEY	1.0M	1.2%	$48M
D. E. Shaw & Co., INC.	1.0M	1.2%	$46M
ARROWSTREET CAPITAL LIMITED PARTNERSHIP	0.9M	1.1%	$43M
DIMENSIONAL FUND ADVISORS LP	0.8M	0.98%	$39M

SEC Form 13F data sets (DERA bulk files). 13F is quarterly, filed up to 45 days late, and covers long US equity positions only, no shorts, no derivatives, nothing held below the reporting threshold.

reading the register…

Drug Manufacturers - Specialty & Generic

Ranks #18 of 28 by Smart Score

Compare peers

INDV-0.43%

Indivior Pharmaceuticals, Inc.

RGC-13%

Regencell Bioscience Holdings Limited

AMRX+0.29%

Amneal Pharmaceuticals, Inc.

LQDA+1.8%

Liquidia Corporation

LNTH+4.0%

Lantheus Holdings, Inc.

SUPN-0.86%

Supernus Pharmaceuticals, Inc.